To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Intrathecal and intravenous clonidine with bupivacaine in children undergoing surgery

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
March 2014

Intrathecal and intravenous clonidine with bupivacaine in children undergoing surgery

Vol: 3| Issue: 3| Number:33| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

An evaluation of intrathecal bupivacaine combined with intrathecal or intravenous clonidine in children undergoing orthopedic surgery: a randomized double-blinded study

Paediatr Anaesth. 2011 Apr;21(4):399-405. doi: 10.1111/j.1460-9592.2011.03543.x

Contributing Authors:
JP Cao XY Miao J Liu XY Shi

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

59 ASA I and II children undergoing orthopedic surgery were randomized to either receive: 1) intrathecal bupivacaine and intravenous saline, 2) intrathecal bupivacaine in combination with clonidine and intravenous saline, or 3) bupivacaine and intravenous clonidine in saline, in order to compare their effects on postoperative analgesia/sedation and intraoperative propofol requirements. Following a...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue